ReviewFrontiers in immunology2024
Immune regulation and organ damage link adiponectin to sepsis.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- GSTP1 as a novel protective target in sepsis: evidence from proteome-wide Mendelian randomization and multi-omics analyses.BMC infectious diseases · 2026Article
- 28-Day Mortality and Prognostic Factors in COPD Patients with Sepsis: A Retrospective Study Using eICU-CRD Database.International journal of chronic obstructive pulmonary disease · 2026Article
- HCQ reverses the immune imbalance related to severe infections following chemotherapy of acute myeloid leukemia and exhibits inhibitory effects on inflammatory cytokine storms.Clinical and experimental medicine · 2025Article
- Harnessing adiponectin for sepsis: current knowledge, clinical insights and future therapies.Critical care (London, England) · 2025Review
- Research status and advances in dexmedetomidine for sepsis‑induced multiple organ dysfunction syndrome (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening syndrome characterized by organ dysfunction, resulting from an uncontrolled or abnormal immune response to infection, which leads to septicemia. It involves a disruption of immune homeostasis, marked by the release of Inflammatory factors and dysfunction of immune cells. Adiponectin is widely recognized as an anti-inflammatory mediator, playing a crucial role in regulating immune cell function and exerting protective effects on tissues and organs. However, the physiological role of adiponectin in septicemia remains unclear due to the condition's association with immune response dysregulation and organ damage. This study focuses on the potential relationship between adiponectin and excessive immune responses, along with organ injury in septicemia. Additionally, we investigate possible explanations for the observed discrepancies in adiponectin levels among critically ill or deceased patients compared to theoretical expectations, aiming to provide valuable insights for clinical diagnostics and therapeutic interventions in sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.